brobert
/
LogseqFMS
1
0
Fork 0
Code Issues Pull Requests Packages Projects Releases Wiki Activity

Auto saved by Logseq

Browse Source
master
Borja Robert 11 months ago
parent 02138ee60d
commit 91f7c3da08
1 changed files with 18 additions and 18 deletions
Show Stats Download Patch File Download Diff File

36
pages/STOP2030___Web.md
Unescape Escape View File

@ -17,27 +17,27 @@
- Qualification at EMA for art. 58 - Qualification at EMA for art. 58
- Safety of IVM up to 600μg/kg alone and in coformulation with albendazole - Safety of IVM up to 600μg/kg alone and in coformulation with albendazole
- Demonstrated efficacy agrainst T. trichiura in a pivotal trial in Sub-Saharan Africa - Demonstrated efficacy agrainst T. trichiura in a pivotal trial in Sub-Saharan Africa
- Timeline y milestones (cuáles se han cumplido?)
- __Proposed safety and effectiveness study__
- *Primary objective*: To evaluate and compare safety of a [[FDC]] against [[Albendazole]] alone via [[MDA]] in two study areas in Kenya and [[Ghana]].
- *Secondary objectives*:
- To evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[Albendazole]] against [[STH]] (T. trichiura, A. lumbricoides, hookworms) [[by]] microscopy
- To evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[Albendazole]] against [[Strongyloides stercolaris]] [[by]] serology
- *Primary goal*: Safety (incidence of SAEs)
- *Secondary goals*: Effectiveness at 21 days and 1 [[year]]; Genomic resistance
- *Sample size*: approx. 20k.
- *Target population*: School based
- *Epidemiologic conditions of the sites*: T. trichiura ongoing transmission areas
- *Countries*: [[Ghana]] and [[Kenya]]
- __Proposed acceptability and feasibility study__
- *Primary goal*: Acceptability and feasibility
- *Secondary goals*: Adherence (3-day regimen), fidelity
- *Countries*: [[Ghana]] and [[Kenya]]
- *Epidemiologic conditions of the sites*: Ongoing [[STH]] deworming activities
-
- ## FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016) - ## FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016)
- Main results of previous STOP projects: ALIVE pivotal Trial - Main results of previous STOP projects: ALIVE pivotal Trial
- Investigadores principales de cada uno de los partners - Investigadores principales de cada uno de los partners
- Timeline y milestones (cuáles se han cumplido?)
- __Proposed safety and effectiveness study__
- *Primary objective*: To evaluate and compare safety of a [[FDC]] against [[Albendazole]] alone via [[MDA]] in two study areas in Kenya and [[Ghana]].
- *Secondary objectives*:
- To evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[Albendazole]] against [[STH]] (T. trichiura, A. lumbricoides, hookworms) [[by]] microscopy
- To evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[Albendazole]] against [[Strongyloides stercolaris]] [[by]] serology
- *Primary goal*: Safety (incidence of SAEs)
- *Secondary goals*: Effectiveness at 21 days and 1 [[year]]; Genomic resistance
- *Sample size*: approx. 20k.
- *Target population*: School based
- *Epidemiologic conditions of the sites*: T. trichiura ongoing transmission areas
- *Countries*: [[Ghana]] and [[Kenya]]
- __Proposed acceptability and feasibility study__
- *Primary goal*: Acceptability and feasibility
- *Secondary goals*: Adherence (3-day regimen), fidelity
- *Countries*: [[Ghana]] and [[Kenya]]
- *Epidemiologic conditions of the sites*: Ongoing [[STH]] deworming activities
-
- Ideas generales importantes - Ideas generales importantes
- Dosing strategies for Ivermectine are being revisited - Dosing strategies for Ivermectine are being revisited
- The fix-dose coformulation of Albendazole/Ivermectine is due to enter regulatory agencies - The fix-dose coformulation of Albendazole/Ivermectine is due to enter regulatory agencies

Write Preview
Loading…
Cancel
Save